Short answer
Day One Biopharmaceuticals, Inc. (DAWN) filed an 8-K current report with the SEC on February 24, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Q4 and full-year 2025 earnings reported Feb 24, 2026: full results in Exhibit 99.1 press release.
Day One Biopharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year 2025 earnings reported Feb 24, 2026: full results in Exhibit 99.1 press release
- Supplemental financial presentation available in Exhibit 99.2 for deeper metrics review
Item 7.01 · Regulation FD Disclosure
- Updated corporate presentation filed Feb 24, 2026 via Reg FD: ensures simultaneous public disclosure of material company information
- Content of presentation not detailed in filing text: investors should review Exhibit 99.3 directly for strategic/pipeline updates
- Filing is explicitly non-incorporated and non-Section 18 liable, limiting legal exposure for forward-looking statements
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Day One Biopharmaceuticals, Inc. 8-K filings
Get the next DAWN 8-K as it lands
Follow DAWN for push alerts, or ask the research agent what this filing means.